<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02490371</url>
  </required_header>
  <id_info>
    <org_study_id>PT-2015-QEHHK</org_study_id>
    <nct_id>NCT02490371</nct_id>
  </id_info>
  <brief_title>Adjunct Low Frequency Repetitive Transcranial Magnetic Stimulation With Physiotherapy Enhance Upper Extremity Function Restoration</brief_title>
  <official_title>The Effectiveness of Combination of Low Frequency Repetitive Transcranial Magnetic Stimulation With Structured Physiotherapy Training Program on Restoring Upper Extremity Function for Patients After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Elizabeth Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hong Kong Polytechnic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Elizabeth Hospital, Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the leading cause of function disability or impairment. Non-promising functional
      return from upper limb rehabilitation has been reported. With the technology advances,
      transcranial magnetic stimulation (TMS), which is a form of non-invasive direct brain
      stimulation, may act as an attenuator in regulating or modulating the cortical excitability
      in order to facilitate cortical re-organization and enhance behavioral performance. Various
      therapeutic exercise protocols have been investigated regarding their efficacy in promoting
      motor recovery of the affected upper limb for patients after stroke and the preliminary
      results were supportive. However, limited numbers of randomized control clinical trials have
      been published in investigating the &quot;priming&quot; or &quot;additive&quot; value of low frequency repetitive
      TMS (rTMS) with combination of structural motor training programs.

      Thus the objective of this study is: to determine the effectiveness of the combination of low
      frequency rTMS on contra-lesional M1 and a structured upper limb motor training program on
      restoring upper limb function among patients with stroke in sub-acute stage. It is
      hypothesized that the rTMS, when combined with a structured motor training program, confers
      additional therapeutic effects on upper limb motor function in subacute stroke patients, when
      compared with the motor training program alone.

      The objectives of this study is to determine the effectiveness of the combination of low
      frequent rTMS on contra-lesional M1 and a structured upper limb motor training program in
      restoring upper limb function among patients with subacute stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will be a randomized double-blinded controlled trial. 26 stroke patients
      with upper limb impairment who are receiving the outpatient physiotherapy service at the
      Queen Elizabeth Hospital and fulfill the eligibility criteria will be recruited and
      randomized into two interventional groups: (1) rTMS + exercise (rTMS-Ex) group and (2)
      Placebo rTMS +exercise (Placebo-Ex) group. Both rTMS-Ex and placebo-Ex group will receive 10
      consecutive treatment sessions (5 sessions per week), which consists of real rTMS stimulation
      (rTMS-ex group) or placebo rTMS (placebo-Ex group), followed by 30-minute structured upper
      limb strengthening and task-specific motor training program. After 2 weeks of brain
      stimulation and motor training, both groups will continue with the same structured motor
      training program for another 10 weeks (2 sessions/ week).

        1. rTMS-Ex Group 10 consecutive sessions (5 days per week for 2 weeks) of 1 Hz low
           frequency repetitive transcranial magnetic stimulation over contra-lesional M1 region
           for 1200 pulse (20 minutes) at 90% motor threshold and immediately followed by 75
           minutes structured physiotherapy upper limb training.

           After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper
           limb training program will continue for another 12 weeks (2 sessions per week)

        2. Placebo-Ex Group 10 consecutive sessions (5 sessions per week for 2 weeks) of placebo
           stimulation over contra-lesional M1 region and immediately followed by 30 minutes of
           structured physiotherapy upper limb training.

      Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2
      sessions per week).

      Evaluation on impairment level, motor performance, physiological measurements and self
      -perceived disability will be performed at 4 time points: before treatment (T0), immediately
      after treatment (T1), one-month follow-up (T2) and three-month follow-up (T3). 2-way repeated
      measures ANOVA will be used to determine whether the rTMS-ex group leads to better outcomes
      than the placebo-ex group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Cortical Excitability From Baseline to at 4th Weeksand 12th Weeks Training in Motor Evoked Potential at 120% Resting MotorThreshold at Affected Hand</measure>
    <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
    <description>Electromyographic (EMG) activity in first doral interossei measured at 120% resting motor threshold. The motor evoked potential amplitude will be measured peak to peak in millivolt(mV). Higher value mean better control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Upper Limb Impairment From Baseline to at 4th Weeks &amp; 12 th Weeks Training in Fugl-Meyer Assessment (FM) Scale</measure>
    <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
    <description>Fugl-Meyer Assessment (FM) scale is a stroke-specific, performance-based impairment index, the scale range from 0 to 66.
25 test items included measurement of movement, coordination, and reflex action of the different parts of the paretic upper extremity. The score could range from 0 to 66. Better motor function was reflected by a higher FMA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Grip Strength From Baseline to at 4th Weeks and at 12th Weeks Training in Force (Kilogram )</measure>
    <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
    <description>Isometric hand grip strength will be measured using the hand-held dynamometer in kilogram (kg). Higher value reflect better hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Upper Limb Function From Baseline to at 4th Weeks Training in Action Research Arm Test (ARAT) Scale</measure>
    <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
    <description>The 19-item Action Research Arm Test has four subscales that assess various aspects of upper limb function (i.e., pinch, grip, grasp, and gross motor). Each item was rated on a 4-point scale from 0 to 3. Scale from 0 to 57.A higher score was indicative of better upper limb function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Reaction Time From Baseline to at 4th Weeks and at 12th Weeks Training in Time Measurement (Seconds)</measure>
    <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
    <description>A simple reaction time will be recorded through a computer system. Time for the patient to reaction to the signal will be measured in seconds (sec). Shorter period of time reflect better reaction time.Lower score means better result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Health Status Measurement From Baseline to at 4th Weeks and at 12th Weeks in Stroke Impact Scale</measure>
    <time_frame>Baseline and at 4th &amp; 12 th weeks</time_frame>
    <description>The 59-item Stroke Impact Scale (SIS) is a stroke-specific, self-report, health status measure. Total range from 0 to 100. Higher score reflect better result.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>(1) rTMS- PT Ex Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(2) Placebo- PT Ex Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low frequency rTMS</intervention_name>
    <description>1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.</description>
    <arm_group_label>(1) rTMS- PT Ex Group</arm_group_label>
    <arm_group_label>(2) Placebo- PT Ex Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>structured physiotherapy upper limb training</intervention_name>
    <description>Structural Physiotherapy upper limb training for 30-minutes</description>
    <arm_group_label>(1) rTMS- PT Ex Group</arm_group_label>
    <arm_group_label>(2) Placebo- PT Ex Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First-ever stroke

          2. Age &gt;60

          3. muscle strength &gt; grade 2 and &lt; grade 5 based on manual muscle testing of hand /
             fingers of the affected upper limb

          4. &gt; 1 month and &lt; 6 months after the onset of stroke

        Exclusion Criteria:

          1. Substantial cognitive impairment with Mini Mental State Test &gt;24

          2. Diagnosis of mental illness

          3. Pathological conditions referred to as contra-indications for rTMS in guideline
             suggested by Wassermann (eg. Cardiac pacemaker, intracranial implants, implanted
             medication pumps, epilepsy)

          4. Unstable cardio-pulmonary conditions -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ka yan LUK</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Physiotherapist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <results_first_submitted>April 17, 2018</results_first_submitted>
  <results_first_submitted_qc>September 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2019</results_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Elizabeth Hospital, Hong Kong</investigator_affiliation>
    <investigator_full_name>HLUKKaYan</investigator_full_name>
    <investigator_title>Senior Physiotherapist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02490371/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A convenient sampling method was adopted. Patients who were diagnosed with their first-ever stroke and referred to the Physiotherapy Department at Queen Elizabeth Hospital for post-stroke rehabilitation between November 2015 to December 2016 were screened for eligibility by an independent physiotherapist using inclusion criterias.</recruitment_details>
      <pre_assignment_details>Exclusion criteria:
Mini Mental State Test score â‰¤ 24;
Mental illness;
Contra-indications to rTMS according to guidelines formulated by Wassermann (e.g., intracranial implants, epilepsy, cardiac pacemaker, implanted medication pumps); 4 Unstable cardio-pulmonary condition.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>(1) rTMS- PT Ex Group</title>
          <description>1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
        <group group_id="P2">
          <title>(2) Placebo- PT Ex Group</title>
          <description>placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week).
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>(1) rTMS- PT Ex Group</title>
          <description>1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
        <group group_id="B2">
          <title>(2) Placebo- PT Ex Group</title>
          <description>placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week).
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="5.8"/>
                    <measurement group_id="B2" value="65.1" spread="3.1"/>
                    <measurement group_id="B3" value="66.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since stroke (weeks)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="5.8"/>
                    <measurement group_id="B2" value="15.1" spread="7"/>
                    <measurement group_id="B3" value="14.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Cortical Excitability From Baseline to at 4th Weeksand 12th Weeks Training in Motor Evoked Potential at 120% Resting MotorThreshold at Affected Hand</title>
        <description>Electromyographic (EMG) activity in first doral interossei measured at 120% resting motor threshold. The motor evoked potential amplitude will be measured peak to peak in millivolt(mV). Higher value mean better control</description>
        <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Cortical Excitability From Baseline to at 4th Weeksand 12th Weeks Training in Motor Evoked Potential at 120% Resting MotorThreshold at Affected Hand</title>
          <description>Electromyographic (EMG) activity in first doral interossei measured at 120% resting motor threshold. The motor evoked potential amplitude will be measured peak to peak in millivolt(mV). Higher value mean better control</description>
          <units>millivolt</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258.3" spread="278"/>
                    <measurement group_id="O2" value="600" spread="374.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323.3" spread="279.5"/>
                    <measurement group_id="O2" value="565" spread="371.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369.1" spread="244.6"/>
                    <measurement group_id="O2" value="586" spread="384.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Upper Limb Impairment From Baseline to at 4th Weeks &amp; 12 th Weeks Training in Fugl-Meyer Assessment (FM) Scale</title>
        <description>Fugl-Meyer Assessment (FM) scale is a stroke-specific, performance-based impairment index, the scale range from 0 to 66.
25 test items included measurement of movement, coordination, and reflex action of the different parts of the paretic upper extremity. The score could range from 0 to 66. Better motor function was reflected by a higher FMA score</description>
        <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Upper Limb Impairment From Baseline to at 4th Weeks &amp; 12 th Weeks Training in Fugl-Meyer Assessment (FM) Scale</title>
          <description>Fugl-Meyer Assessment (FM) scale is a stroke-specific, performance-based impairment index, the scale range from 0 to 66.
25 test items included measurement of movement, coordination, and reflex action of the different parts of the paretic upper extremity. The score could range from 0 to 66. Better motor function was reflected by a higher FMA score</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="13.9"/>
                    <measurement group_id="O2" value="48.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="11.9"/>
                    <measurement group_id="O2" value="49.9" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="9.6"/>
                    <measurement group_id="O2" value="53.3" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Grip Strength From Baseline to at 4th Weeks and at 12th Weeks Training in Force (Kilogram )</title>
        <description>Isometric hand grip strength will be measured using the hand-held dynamometer in kilogram (kg). Higher value reflect better hand grip strength</description>
        <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Grip Strength From Baseline to at 4th Weeks and at 12th Weeks Training in Force (Kilogram )</title>
          <description>Isometric hand grip strength will be measured using the hand-held dynamometer in kilogram (kg). Higher value reflect better hand grip strength</description>
          <units>kilgograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="11.3"/>
                    <measurement group_id="O2" value="13.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="10.8"/>
                    <measurement group_id="O2" value="13.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="10.1"/>
                    <measurement group_id="O2" value="14.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Upper Limb Function From Baseline to at 4th Weeks Training in Action Research Arm Test (ARAT) Scale</title>
        <description>The 19-item Action Research Arm Test has four subscales that assess various aspects of upper limb function (i.e., pinch, grip, grasp, and gross motor). Each item was rated on a 4-point scale from 0 to 3. Scale from 0 to 57.A higher score was indicative of better upper limb function.</description>
        <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Upper Limb Function From Baseline to at 4th Weeks Training in Action Research Arm Test (ARAT) Scale</title>
          <description>The 19-item Action Research Arm Test has four subscales that assess various aspects of upper limb function (i.e., pinch, grip, grasp, and gross motor). Each item was rated on a 4-point scale from 0 to 3. Scale from 0 to 57.A higher score was indicative of better upper limb function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="17.8"/>
                    <measurement group_id="O2" value="41.1" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4" spread="11.4"/>
                    <measurement group_id="O2" value="41.1" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="8.9"/>
                    <measurement group_id="O2" value="43.2" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Reaction Time From Baseline to at 4th Weeks and at 12th Weeks Training in Time Measurement (Seconds)</title>
        <description>A simple reaction time will be recorded through a computer system. Time for the patient to reaction to the signal will be measured in seconds (sec). Shorter period of time reflect better reaction time.Lower score means better result</description>
        <time_frame>Baseline and at 4th weeks and at 12th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Reaction Time From Baseline to at 4th Weeks and at 12th Weeks Training in Time Measurement (Seconds)</title>
          <description>A simple reaction time will be recorded through a computer system. Time for the patient to reaction to the signal will be measured in seconds (sec). Shorter period of time reflect better reaction time.Lower score means better result</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985.8" spread="439.9"/>
                    <measurement group_id="O2" value="654.2" spread="285.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="902.2" spread="398.6"/>
                    <measurement group_id="O2" value="651.7" spread="285.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="837.3" spread="309.1"/>
                    <measurement group_id="O2" value="637.9" spread="291.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Health Status Measurement From Baseline to at 4th Weeks and at 12th Weeks in Stroke Impact Scale</title>
        <description>The 59-item Stroke Impact Scale (SIS) is a stroke-specific, self-report, health status measure. Total range from 0 to 100. Higher score reflect better result.</description>
        <time_frame>Baseline and at 4th &amp; 12 th weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rTMS Group + Exercise</title>
            <description>Patient with rTMS and 30 minutes exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo+ Exercise</title>
            <description>Placebo stimulation with exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Health Status Measurement From Baseline to at 4th Weeks and at 12th Weeks in Stroke Impact Scale</title>
          <description>The 59-item Stroke Impact Scale (SIS) is a stroke-specific, self-report, health status measure. Total range from 0 to 100. Higher score reflect better result.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="13.3"/>
                    <measurement group_id="O2" value="65.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="8.5"/>
                    <measurement group_id="O2" value="69.6" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12th week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="6.9"/>
                    <measurement group_id="O2" value="72.7" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event during the rTMS stimulation , following the whole study period included at 4th weeks up to end of study period at 12th weeks had been reported and recorded.</time_frame>
      <desc>Headache, seizure</desc>
      <group_list>
        <group group_id="E1">
          <title>(1) rTMS- PT Ex Group</title>
          <description>1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.
After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
        <group group_id="E2">
          <title>(2) Placebo- PT Ex Group</title>
          <description>placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.
Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week).
Low frequency rTMS: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
structured physiotherapy upper limb training: Structural Physiotherapy upper limb training for 30-minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <description>Transcranial magnetic stimulation may casue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helen LUK</name_or_title>
      <organization>QEHHongKong</organization>
      <phone>852-9208 5366</phone>
      <email>clkyz02@ha.org.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

